NSC 290205-based Therapy in Murine Pancreatic Adenocarcinoma PAN02 in Combination with Adriamycin (ADR)

• Published in: Anticancer research Vol. 26; no. 1A; pp. 243 - 247
• Main Authors: PAPAGEORGIOU, Athanasios, ANDREADIS, Charalambos, BOUTIS, Anastasios, LIALIARIS, Theodoros S, MOURATIDOU, Despina
• Format: Journal Article
• Language: English
• Published: Attiki International Institute of Anticancer Research 01-01-2006
• Subjects: Animals; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Azasteroids - administration & dosage; Azasteroids - pharmacology; Biological and medical sciences; Carcinoma, Pancreatic Ductal - drug therapy; Cell Line, Tumor; Chemotherapy; Cyclophosphamide - administration & dosage; Cyclophosphamide - pharmacology; Doxorubicin - administration & dosage; Female; Male; Medical sciences; Mice; Mice, Inbred C57BL; Nitrogen Mustard Compounds - administration & dosage; Nitrogen Mustard Compounds - pharmacology; Pancreatic Neoplasms - drug therapy; Pharmacology. Drug treatments; Prednisone - administration & dosage; Tumors; Vincristine - administration & dosage; Antineoplastic agent; pancreatic adenocarcinoma; NSC 290205; Doxorubicin; mice; Ester; Isomerases; Cancerology; Pancreas cancer; Established cell line; CHOP; Pancreatic disease; DNA topoisomerase (ATP-hydrolysing); Drug combination; Enzyme; Rodentia; Enzyme inhibitor; Malignant tumor; Vertebrata; Mammalia; Treatment; Mouse; Animal; adriamycin; CHOP regimen; Digestive diseases; Anthracyclins; Therapeutic protocol; Pancreas adenocarcinoma; Comparative study
• ISSN: 0250-7005; 1791-7530

Background: NSC 290205 (A) is a hybrid synthetic antitumor ester, which combines a D-lactam derivative of androsterone and
nitrogen mustard. In this study, the antitumor activity of A in combination with ADR (AHOP) was investigated in comparison
with the standard CHOP regimen. Materials and Methods: PAN02 adenocarcinoma was used in this study. C 57 Bl mice were used for chemotherapy evaluation. The activity was assessed from the inhibition of tumor growth and the oncostatic
parameter T/C%. Results: Treatment with A or cyclophosphamide produced almost equal borderline activity. Moreover, both the
CHOP and AHOP regimens showed significant and comparable antitumor effects. AHOP caused the maximum effect, inhibiting tumor
growth by 56.8%. CHOP was less effective, producing 47.7% tumor inhibition. Conclusion: It is very likely that the D-lactamic
steroid (androstan) alkylator for A, containing the amide group -NH-CO-, combined with ADR which intercalates between DNA
base-pairs, is the explanation for the higher activity of AHOP as compared to CHOP.